Does Nirsevimab Prevent Lower Respiratory Infections Caused by Respiratory Syncytial Virus?
- Kelsey Sullivan; Brynne Sullivan
Access Resources
About
This study examines nirsevimab, a monoclonal antibody that helps prevent respiratory syncytial virus (RSV) infections in infants. It found that one injection of nirsevimab significantly reduced RSV-related lower respiratory tract infections compared to a placebo. It was effective for up to 150 days and had a good safety profile. The FDA approved it for use in newborns and infants during their first RSV season, as well as children up to 24 months who are at risk of severe RSV disease. Nirsevimab is expected to reduce the burden of RSV among young children significantly.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.